Acquired factor VIII inhibitors in a non-hemophilic patient
Case report
Keywords:
HEMORRHAGE, FACTOR VIII, BLOOD COAGULATION FACTOR INHIBITORS
Abstract
A young woman showed an hemorragic syndrome secondary to an acquired deficit coagulation due to antibodies factor VIII inhibitors. Even if coagulation inhibitors are rare in non-hemophilic patients, this case is interesting since it shows a serious condition thay may produce death. Early diagnosis and treatment, as well as defining whether it is a primary alteration or a consequence of a subtle disease, are of capital importance. The paper includes a description of the steps to determine diagnosis and a review of the current therapeutic tools.
References
(1) Castillo R. Hipocaoagulabilidades adquiridas: Síndrome de la coagulación intravascular diseminada (CID) Deficiencias complejas de la hemostasia. In: Sans-Sabrafen J, Besses C, Castillo R, Florensa L, Pardo P, Vives Corrons J. eds. Hematología clínica. 3 ed. Barcelona: Mosby/Doyma, 1994: 533-48.
(2) Castillo R, Margal S. Hipocoagulabilidades congénitas: hemofilia, enfermedad de Von Willebrand y procesos afines. In: Sans-Sabrafen J, Besses C, Castillo R, Florensa L, Pardo P, Vives Corrons J. eds. Hematología clínica. 3 ed. Barcelona: Mosby, 1994: 499-514.
(3) Schafer A. Atención del paciente con hemorragia y trombosis. In: Goldman L, Bennet JC. ed. Tratado de medicina interna de Cecil. 21 ed. México: McGraw-Hill / Interamericana, 2002: 1096-101. v.1
(4) Pintor Holguín E, Velasco Arribas M, Mínguez García P, Ramón Pardo P, Ruiz Yagüe M, Fernández-Cruz Pérez A. Déficit adquirido del factor VIII. An Med Interna (Madrid). 2001: 18(1): 49. Disponible en: http://wwwscielo.isciii.es/scielo.php?script=sci_arttext&pid=S0212-71992001000100017&lng=en&nrm=iso (Consulta: 10/set 2005).
(5) Suchman A, Griner P. Diagnostic uses of the activated partial thromboplastin time and prothrombin time. Ann Intern Med. 1986; 104 (6): 810-6.
(6) Castillo R, Escolar G, Bastida E. Fisiología y exploración de la hemostasia. In: Sans-Sabrafen J, Besses C, Castillo R, Florensa L, Pardo P, Vives Corrons J. eds. Hematología clínica. 3 ed. Barcelona: Mosby, 1994: 481-98.
(7) Rick M, Walsh C, Key N. Congenital bleeding disorders. Hematology Am Soc Hematol Educ Program. 2003; 559-74.
(8) Tabeada C. Actualidades en el tratamiento de la hemofilia. Gac Med Méx 2003; 139 (Supl 2): 43-6.
(9) Islam S, Abdullah S. Treatment of acquired factor VIII inhibitor associated with childhood-onset systemic lupus erythematosus. Ann Saudi Med 1999; 19(2): 125-7.
(10) Díaz L, Izaurralde H, Nese M. Hemofilia adquirida: inhibidor espontáneo del factor VIII. Congreso de Medicina Interna, 29. Montevideo, 2000.
(11) Freldman M, Steinmar L. Design of effective immunotherapy for human autoimmunity. Nature 2005; 435(2): 612-9.
(12) Sfitakis P, Boletis J, Tsokos G. Rituximab anti-B-cell theraphy in systemic lupus erythematosus: pointing to the future. Curr Op Rheumat 2005; 17: 550-7.
(13) Wiestner A, Cho E. Rituximab in the treatment of acquired factor VIII inhibitors. Blood 2002; 100(9): 3426-8.
(14) Stasi R, Brunetti M. Selective B cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 2004; 103(12) : 4424-8.
(2) Castillo R, Margal S. Hipocoagulabilidades congénitas: hemofilia, enfermedad de Von Willebrand y procesos afines. In: Sans-Sabrafen J, Besses C, Castillo R, Florensa L, Pardo P, Vives Corrons J. eds. Hematología clínica. 3 ed. Barcelona: Mosby, 1994: 499-514.
(3) Schafer A. Atención del paciente con hemorragia y trombosis. In: Goldman L, Bennet JC. ed. Tratado de medicina interna de Cecil. 21 ed. México: McGraw-Hill / Interamericana, 2002: 1096-101. v.1
(4) Pintor Holguín E, Velasco Arribas M, Mínguez García P, Ramón Pardo P, Ruiz Yagüe M, Fernández-Cruz Pérez A. Déficit adquirido del factor VIII. An Med Interna (Madrid). 2001: 18(1): 49. Disponible en: http://wwwscielo.isciii.es/scielo.php?script=sci_arttext&pid=S0212-71992001000100017&lng=en&nrm=iso (Consulta: 10/set 2005).
(5) Suchman A, Griner P. Diagnostic uses of the activated partial thromboplastin time and prothrombin time. Ann Intern Med. 1986; 104 (6): 810-6.
(6) Castillo R, Escolar G, Bastida E. Fisiología y exploración de la hemostasia. In: Sans-Sabrafen J, Besses C, Castillo R, Florensa L, Pardo P, Vives Corrons J. eds. Hematología clínica. 3 ed. Barcelona: Mosby, 1994: 481-98.
(7) Rick M, Walsh C, Key N. Congenital bleeding disorders. Hematology Am Soc Hematol Educ Program. 2003; 559-74.
(8) Tabeada C. Actualidades en el tratamiento de la hemofilia. Gac Med Méx 2003; 139 (Supl 2): 43-6.
(9) Islam S, Abdullah S. Treatment of acquired factor VIII inhibitor associated with childhood-onset systemic lupus erythematosus. Ann Saudi Med 1999; 19(2): 125-7.
(10) Díaz L, Izaurralde H, Nese M. Hemofilia adquirida: inhibidor espontáneo del factor VIII. Congreso de Medicina Interna, 29. Montevideo, 2000.
(11) Freldman M, Steinmar L. Design of effective immunotherapy for human autoimmunity. Nature 2005; 435(2): 612-9.
(12) Sfitakis P, Boletis J, Tsokos G. Rituximab anti-B-cell theraphy in systemic lupus erythematosus: pointing to the future. Curr Op Rheumat 2005; 17: 550-7.
(13) Wiestner A, Cho E. Rituximab in the treatment of acquired factor VIII inhibitors. Blood 2002; 100(9): 3426-8.
(14) Stasi R, Brunetti M. Selective B cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 2004; 103(12) : 4424-8.
Published
2006-12-31
How to Cite
1.
Arias S, Fonsalía V, Casavieja G, Ruiz Díaz E, Chapper C, Magariños A. Acquired factor VIII inhibitors in a non-hemophilic patient. Rev. Méd. Urug. [Internet]. 2006Dec.31 [cited 2024Nov.17];22(4):305-10. Available from: http://www2.rmu.org.uy/ojsrmu311/index.php/rmu/article/view/664
Section
Clinical Cases
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
